<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03899792</url>
  </required_header>
  <id_info>
    <org_study_id>LOXO-RET-18036</org_study_id>
    <secondary_id>2019‐000212‐28</secondary_id>
    <nct_id>NCT03899792</nct_id>
  </id_info>
  <brief_title>A Study of Oral LOXO-292 in Pediatric Patients With Advanced Solid or Primary Central Nervous System Tumors</brief_title>
  <acronym>LIBRETTO-121</acronym>
  <official_title>A Phase 1/2 Study of the Oral RET Inhibitor LOXO 292 in Pediatric Patients With Advanced RET-Altered Solid or Primary Central Nervous System Tumors</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Loxo Oncology, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Loxo Oncology, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is an open-label, multi-center Phase 1/2 study of oral LOXO-292 in pediatric patients
      with an activating RET alteration and an advanced solid or primary CNS tumor.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study includes 2 parts: phase 1 (dose escalation) and phase 2 (dose expansion). In phase
      1, patients will be enrolled using a rolling 6 dose escalation scheme. The starting dose of
      LOXO-292 is equivalent to the adult recommended phase 2 dose of 160mg BID. Once the MTD
      and/or RP2D is identified, patients will be enrolled to one of four phase 2 dose expansion
      cohorts depending on tumor histology and tumor genotype. Cycle length will be 28 days.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">July 1, 2019</start_date>
  <completion_date type="Anticipated">October 2022</completion_date>
  <primary_completion_date type="Anticipated">November 2021</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>Yes</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>To determine the safety of oral LOXO-292 in pediatric patients with advanced solid tumors: Dose limiting toxicities (DLTs)</measure>
    <time_frame>During the first 28-day cycle of LOXO-292 treatment</time_frame>
    <description>For Phase 1</description>
  </primary_outcome>
  <primary_outcome>
    <measure>To determine the safety of oral LOXO-292 in pediatric patients with primary central nervous system (CNS) tumors: Dose limiting toxicities (DLTs)</measure>
    <time_frame>During the first 28-day cycle of LOXO-292 treatment</time_frame>
    <description>For Phase 1</description>
  </primary_outcome>
  <primary_outcome>
    <measure>ORR based on RECIST 1.1 per IRC</measure>
    <time_frame>Baseline to Progressive Disease or Death due to any cause (Estimated up to 12 months)</time_frame>
    <description>For Phase 2</description>
  </primary_outcome>
  <primary_outcome>
    <measure>ORR based on RANO per IRC</measure>
    <time_frame>Baseline to Progressive Disease or Death due to any cause (Estimated up to 12 months)</time_frame>
    <description>For Phase 2</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Plasma concentrations of LOXO-292</measure>
    <time_frame>Days 1 &amp; 8 of Cycle 1, Day 1 of Cycle 3 and Day 8 after Intra-patient Dose Escalation (each cycle is 28 days)</time_frame>
    <description>Phase 1</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AUC0-24 of LOXO-292</measure>
    <time_frame>Days 1 &amp; 8 of Cycle 1, Day 1 of Cycle 3 and Day 8 after Intra-patient Dose Escalation (each cycle is 28 days)</time_frame>
    <description>Phase 1 &amp; Phase 2</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cmax of LOXO-292</measure>
    <time_frame>Days 1 &amp; 8 of Cycle 1, Day 1 of Cycle 3 and Day 8 after Intra-patient Dose Escalation (each cycle is 28 days)</time_frame>
    <description>Phase 1 &amp; Phase 2</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tmax of LOXO-292</measure>
    <time_frame>Days 1 &amp; 8 of Cycle 1, Day 1 of Cycle 3 and Day 8 after Intra-patient Dose Escalation (each cycle is 28 days)</time_frame>
    <description>Phase 1 &amp; Phase 2</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Recommended LOXO-292 Dose for Phase 2 (Maximum Tolerated Dose [MTD])</measure>
    <time_frame>Cycle 1 (28 days)</time_frame>
    <description>For Phase 1</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To assess the preliminary anti-tumor activity of LOXO-292 in pediatric patients with tumors harboring an activating RET alteration as determined by ORR based on RECIST v1.1</measure>
    <time_frame>Baseline to Progressive Disease or Death due to any cause (Estimated up to 12 months)</time_frame>
    <description>For Phase 1</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes from baseline in pain measures as measured by Wong Baker Faces scales. Wong-Baker Faces Pain Scale includes pictures of facial expressions with correlating scores of 0 being 'no hurt' and 10 being 'hurts worst'.</measure>
    <time_frame>Up to 24 months</time_frame>
    <description>For Phase 1</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes from baseline in health related quality of life measures as measured by Pediatric Quality of Life Inventory Core. PedsQoL includes a list of problems with scores of 0 being 'never a problem' and 4 being 'almost always a problem'.</measure>
    <time_frame>Up to 24 months</time_frame>
    <description>For Phase 1</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Objective Response Rate as assessed by RECIST v1.1, as assessed by investigator</measure>
    <time_frame>Approximately every 8 weeks for one year, then every 12 weeks, and 7 days after the last dose (for up to 2 years) in patients who have not progressed.</time_frame>
    <description>For Phase 2</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Objective Response Rate as assessed by RANO, as assessed by investigator</measure>
    <time_frame>Approximately every 8 weeks for one year, then every 12 weeks, and 7 days after the last dose (for up to 2 years) in patients who have not progressed.</time_frame>
    <description>For Phase 2</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of response (DOR) as assessed by the Investigator</measure>
    <time_frame>Approximately every 8 weeks for one year, then every 12 weeks, and 7 days after the last dose (for up to 2 years) in patients who have not progressed.</time_frame>
    <description>For Phase 2</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of response (DOR) as assessed by the IRC</measure>
    <time_frame>Approximately every 8 weeks for one year, then every 12 weeks, and 7 days after the last dose (for up to 2 years) in patients who have not progressed.</time_frame>
    <description>For Phase 2</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression free survival (PFS) as assessed by the Investigator</measure>
    <time_frame>Approximately every 8 weeks for one year, then every 12 weeks, and 7 days after the last dose (for up to 2 years) in patients who have not progressed.</time_frame>
    <description>For Phase 2</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression free survival (PFS) as assessed by the IRC</measure>
    <time_frame>Approximately every 8 weeks for one year, then every 12 weeks, and 7 days after the last dose (for up to 2 years) in patients who have not progressed.</time_frame>
    <description>For Phase 2</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival (OS)</measure>
    <time_frame>Approximately every 8 weeks for one year, then every 12 weeks, and 7 days after the last dose (for up to 2 years) in patients who have not progressed.</time_frame>
    <description>For Phase 2</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical Benefit Rate (by Investigator)</measure>
    <time_frame>Approximately every 8 weeks for one year, then every 12 weeks, 7 days after the last dose (for up to 2 years) in patients who have not progressed.</time_frame>
    <description>For Phase 2</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical Benefit Rate (by IRC)</measure>
    <time_frame>Approximately every 8 weeks for one year, then every 12 weeks, 7 days after the last dose (for up to 2 years) in patients who have not progressed.</time_frame>
    <description>For Phase 2</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Frequency of AEs</measure>
    <time_frame>From the time of informed consent, for approximately 24 months (or earlier if the patient discontinues from the study), and through Safety Follow-up (28 days after the last dose)</time_frame>
    <description>For Phase 2</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To evaluate the concordance of prior molecular profiling that detected a RET alteration within the subject's tumor with diagnostic tests being evaluated by the Sponsor</measure>
    <time_frame>6 months</time_frame>
    <description>For Phase 2</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase 2: Post-operative stage on patients treated with LOXO-292.</measure>
    <time_frame>Up to 3 years</time_frame>
    <description>Tumor stage is described according to the TNM Classification of malignant tumors of the Union for International Cancer Control (UICC).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase 2: Surgical margin status in patients treated with LOXO-292.</measure>
    <time_frame>Up to 3 years</time_frame>
    <description>Tumor margins after surgery are classified into four groups using the International Cancer Control (UICC)-R classification and the Intergroup Rhabdomyosarcoma Staging (IRS) systems: 1) Complete tumor resection with histologically free margins, 2) Macroscopic resection but invaded margins on histology, 3)Macroscopic residual tumor and 4) Distant metastatic tumor.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Descriptive analysis of pretreatment surgical plan</measure>
    <time_frame>Up to 3 years</time_frame>
    <description>For Phase 2</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Descriptive analysis of post-treatment plans</measure>
    <time_frame>Up to 3 years</time_frame>
    <description>For Phase 2</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Medullary Thyroid Cancer</condition>
  <condition>Infantile Myofibromatosis</condition>
  <condition>Infantile Fibrosarcoma</condition>
  <condition>Papillary Thyroid Cancer</condition>
  <condition>Soft Tissue Sarcoma</condition>
  <arm_group>
    <arm_group_label>LOXO-292</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Phase 1- Dose Escalation and determination of MTD; multiple dose levels of LOXO-292 to be evaluated; Phase 2 - The maximum tolerated dose (MTD)/recommended dose from Phase 1</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>LOXO-292</intervention_name>
    <description>Oral LOXO-292</description>
    <arm_group_label>LOXO-292</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Advanced or metastatic solid or primary CNS tumor which has failed standard of care
             therapies

          -  Evidence of an activating RET gene alteration in the tumor and/ or blood

          -  Measurable or non-measurable disease

          -  Karnofsky (patients 16 years and older) or Lansky (patients younger than 16)
             performance score of at least 50.

          -  Patient with primary CNS tumors or cerebral metastases must be neurologically stable
             for 7 days prior and must not have required increasing doses of steroids within the
             last 7 days.

          -  Adequate hematologic, hepatic and renal function.

          -  Ability to receive study drug therapy orally or via gastric access

          -  Willingness of men and women of reproductive potential to observe conventional and
             effective birth control

        Exclusion Criteria:

          -  Major surgery within 4 weeks prior to planned start of LOXO-292.

          -  Clinically significant, uncontrolled cardiac, cardiovascular disease or history of
             myocardial infarction within 6 months prior to planned start of LOXO-292.

          -  Active uncontrolled systemic bacterial, viral, fungal or parasitic infection.

          -  Clinically significant active malabsorption syndrome.

          -  Pregnancy or lactation

          -  Uncontrolled symptomatic hyperthyroidism or hypothyroidism (i.e. the patient required
             a modification to current thyroid medication in the 7 days before start of LOXO-292).

          -  Uncontrolled symptomatic hypercalcemia or hypocalcemia.

          -  Current treatment with certain strong cytochrome P450 3A4 (CYP3A4) inhibitors or
             inducers.

          -  Known hypersensitivity to any of the components of the investigational agent, LOXO-292
             or Ora-Sweet® SF and OraPlus®, for patients who will receive LOXO-292 suspension.

          -  Current treatment with proton pump inhibitors.

          -  Prior treatment with a selective RET inhibitor(s) (including investigational selective
             RET inhibitor[s]).
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>6 Months</minimum_age>
    <maximum_age>21 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Elizabeth Olek, DO, MPH</last_name>
    <role>Study Director</role>
    <affiliation>Loxo Oncology</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Patient Advocacy</last_name>
    <phone>855-RET-4-292 (855-738-4292)</phone>
    <email>clinicaltrials@loxooncology.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Children's Hospital Los Angeles</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90027</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Dana Farber Cancer Institute</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02215</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Memorial Sloan Kettering Cancer Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10065</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Cincinnati Children's Hospital Medical Center</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45229</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Children's Hospital of Philadelphia</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>St. Jude Children's Research Hospital, Inc.</name>
      <address>
        <city>Memphis</city>
        <state>Tennessee</state>
        <zip>38105</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>University of Texas, Southwestern Medical Center</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75235</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Texas Children's Hospital</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Seattle Children's Hospital</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98105</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2019</verification_date>
  <study_first_submitted>February 6, 2019</study_first_submitted>
  <study_first_submitted_qc>April 1, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">April 2, 2019</study_first_posted>
  <last_update_submitted>October 3, 2019</last_update_submitted>
  <last_update_submitted_qc>October 3, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">October 4, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Loxo</keyword>
  <keyword>LOXO-292</keyword>
  <keyword>KIF5B-RET</keyword>
  <keyword>M918T</keyword>
  <keyword>CCDC6-RET</keyword>
  <keyword>RET-PTC1</keyword>
  <keyword>NCOA4-RET</keyword>
  <keyword>RET-PTC</keyword>
  <keyword>RET-PTC3</keyword>
  <keyword>RET-PTC4</keyword>
  <keyword>PRKAR1A-RET</keyword>
  <keyword>RET-PTC2</keyword>
  <keyword>GOLGA5-RET</keyword>
  <keyword>RET-PTC5</keyword>
  <keyword>ERC1-RET</keyword>
  <keyword>KTN1-RET</keyword>
  <keyword>RET-PTC8</keyword>
  <keyword>HOOK3-RET</keyword>
  <keyword>PCM1-RET</keyword>
  <keyword>TRIM24-RET</keyword>
  <keyword>RET-PTC6</keyword>
  <keyword>TRIM27-RET</keyword>
  <keyword>TRIM33-RET</keyword>
  <keyword>RET-PTC7</keyword>
  <keyword>AKAP13-RET</keyword>
  <keyword>FKBP15-RET</keyword>
  <keyword>SPECC1L-RET</keyword>
  <keyword>TBL1XR1-RET</keyword>
  <keyword>BCR-RET</keyword>
  <keyword>FGRF1OP-RET</keyword>
  <keyword>RFG8-RET</keyword>
  <keyword>RET-PTC9</keyword>
  <keyword>ACBD5-RET</keyword>
  <keyword>MYH13-RET</keyword>
  <keyword>CUX1-RET</keyword>
  <keyword>KIAA1468-RET</keyword>
  <keyword>FRMD4A-RET</keyword>
  <keyword>SQSTM1-RET</keyword>
  <keyword>AFAP1L2-RET</keyword>
  <keyword>PPFIBP2-RET</keyword>
  <keyword>EML4-RET</keyword>
  <keyword>PARD3-RET</keyword>
  <keyword>G533C</keyword>
  <keyword>C609F</keyword>
  <keyword>C609G</keyword>
  <keyword>C609R</keyword>
  <keyword>C609S</keyword>
  <keyword>C609Y</keyword>
  <keyword>C611F</keyword>
  <keyword>C611G</keyword>
  <keyword>C611S</keyword>
  <keyword>C611Y</keyword>
  <keyword>C611W</keyword>
  <keyword>C618F</keyword>
  <keyword>C618R</keyword>
  <keyword>C618S</keyword>
  <keyword>C620F</keyword>
  <keyword>C620R</keyword>
  <keyword>C620S</keyword>
  <keyword>C630R</keyword>
  <keyword>C630Y</keyword>
  <keyword>D631Y</keyword>
  <keyword>C634F</keyword>
  <keyword>C634G</keyword>
  <keyword>C634R</keyword>
  <keyword>C634S</keyword>
  <keyword>C634W</keyword>
  <keyword>C634Y</keyword>
  <keyword>K666E</keyword>
  <keyword>E768D</keyword>
  <keyword>L790F</keyword>
  <keyword>V804L</keyword>
  <keyword>V804M</keyword>
  <keyword>A883F</keyword>
  <keyword>S891A</keyword>
  <keyword>R912P</keyword>
  <keyword>CLIP1-RET</keyword>
  <keyword>Y806C</keyword>
  <keyword>RET fusion</keyword>
  <keyword>RET alteration</keyword>
  <keyword>RET mutation</keyword>
  <keyword>RET rearrangement</keyword>
  <keyword>RET translocation</keyword>
  <keyword>Neoplasms by Site</keyword>
  <keyword>Neoplasms</keyword>
  <keyword>Non-Small Cell Lung Cancer</keyword>
  <keyword>Lung Neoplasms</keyword>
  <keyword>Carcinoma, Non-Small-Cell Lung</keyword>
  <keyword>Cancer of Lung</keyword>
  <keyword>Cancer of the Lung</keyword>
  <keyword>Lung Cancer</keyword>
  <keyword>Neoplasms, Lung</keyword>
  <keyword>Neoplasms, Pulmonary</keyword>
  <keyword>Pulmonary Cancer</keyword>
  <keyword>Pulmonary Neoplasms</keyword>
  <keyword>Respiratory Tract Neoplasms</keyword>
  <keyword>Lung Diseases</keyword>
  <keyword>Respiratory Tract Diseases</keyword>
  <keyword>Carcinoma, Bronchogenic</keyword>
  <keyword>Bronchial Neoplasms</keyword>
  <keyword>Medullary Thyroid Cancer</keyword>
  <keyword>Papillary Thyroid Cancer</keyword>
  <keyword>Thyroid Diseases</keyword>
  <keyword>Thyroid Neoplasms</keyword>
  <keyword>Cancer of the Thyroid</keyword>
  <keyword>Cancer of Thyroid</keyword>
  <keyword>Neoplasms, Thyroid</keyword>
  <keyword>Thyroid Adenoma</keyword>
  <keyword>Thyroid Cancer</keyword>
  <keyword>Thyroid Carcinoma</keyword>
  <keyword>Endocrine System Diseases</keyword>
  <keyword>Endocrine Gland Neoplasms</keyword>
  <keyword>Head and Neck Neoplasms</keyword>
  <keyword>Thoracic Neoplasms</keyword>
  <keyword>CNS tumor</keyword>
  <keyword>Primary CNS tumor</keyword>
  <keyword>Colonic Neoplasms</keyword>
  <keyword>Cancer of Colon</keyword>
  <keyword>Cancer of the Colon</keyword>
  <keyword>Colon Cancer</keyword>
  <keyword>Colon Neoplasms</keyword>
  <keyword>Colonic Cancer</keyword>
  <keyword>Neoplasms, Colonic</keyword>
  <keyword>Malignant tumor of Breast</keyword>
  <keyword>Mammary Cancer</keyword>
  <keyword>Mammary Carcinoma, Human</keyword>
  <keyword>Mammary Neoplasm, Human</keyword>
  <keyword>Neoplasms, Breast</keyword>
  <keyword>Tumors, Breast</keyword>
  <keyword>Human Mammary Carcinoma</keyword>
  <keyword>Malignant Neoplasm of Breast</keyword>
  <keyword>Breast Carcinoma</keyword>
  <keyword>Breast Tumors</keyword>
  <keyword>Cancer of the Breast</keyword>
  <keyword>Breast Neoplasms</keyword>
  <keyword>Breast Cancer</keyword>
  <keyword>RET Inhibitor</keyword>
  <keyword>MTC</keyword>
  <keyword>NSCLC</keyword>
  <keyword>Soft tissue sarcoma</keyword>
  <keyword>Infantile Myofibromatosis</keyword>
  <keyword>Infantile Fibrosarcoma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sarcoma</mesh_term>
    <mesh_term>Thyroid Neoplasms</mesh_term>
    <mesh_term>Nervous System Neoplasms</mesh_term>
    <mesh_term>Central Nervous System Neoplasms</mesh_term>
    <mesh_term>Thyroid Cancer, Papillary</mesh_term>
    <mesh_term>Fibrosarcoma</mesh_term>
    <mesh_term>Myofibromatosis</mesh_term>
    <mesh_term>Thyroid Diseases</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

